Arbutus Biopharma Gets FDA Fast-Track Designation for Imdusiran in Chronic Hepatitis B

Published: 2026-04-15 08:21:49 ET ABUS

Published on 04/15/2026 at 08:21 am EDT

By Colin Kellaher

Arbutus Biopharma has won U.S. Food and Drug Administration fast-track designation for its proposed imdusiran treatment for chronic hepatitis B, a serious liver infection.

The Warminster, Pa., clinical-stage biopharmaceutical company said imdusiran has achieved functional cure for 10 chronic hepatitis B patients in clinical trials to date.

The FDA's fast-track program is designed to facilitate the development and expedite the review of treatments for serious or potentially life-threatening illnesses with high unmet medical needs.

Write to Colin Kellaher at [email protected]

(END) Dow Jones Newswires

04-15-26 0820ET